Iqvia Holdings is a global leader in advancing healthcare by providing data analytics, technology, and consulting services to the pharmaceutical and life sciences industries. The company specializes in helping organizations improve their clinical trials, optimize research and development processes, and enhance patient engagement. By leveraging its extensive data assets and innovative technology platforms, Iqvia aids clients in making informed decisions that drive efficiency and effectiveness in bringing new therapies to market.
Elliott Investment Management was busy in the third quarter. According to a new 13-F filing with the SEC, the activist made several portfolio moves, with multiple new positions focused around travel and lodging.
RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age group and reducing demand by two-thirds compared to last year.
A flat week that was anticipated, one notable event was China's stimulus package announcement, which sent China-related stocks soaring. Most of these stocks surged without prior consolidations/warning signs. This week, we anticipate some retracement.
Veeva Systems recently announced its quarterly results that continued to impress the market. Vault CRM continues to remain the buzz word for Veeva as Salesforce gears up for more direct competition with it.
RBC Capital Markets has initiated coverage on IQVIA highlighting the company's extensive data assets as its key differentiator. It has faced challenges in investor sentiment and EPS growth due to the COVID-19 pandemic, rising interest expenses, and a weaker biopharma funding environment.
Wall Street started the new week on a positive note, with all major indices in the green. A rebound in tech stocks following last week’s dips bolstered overall investor sentiment.
